• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于上市后安全监测中不良事件信号检测的逻辑回归似然比检验分析

Logistic Regression Likelihood Ratio Test Analysis for Detecting Signals of Adverse Events in Post-market Safety Surveillance.

作者信息

Nam Kijoeng, Henderson Nicholas C, Rohan Patricia, Woo Emily Jane, Russek-Cohen Estelle

机构信息

a Merck Research Labs, Merck & Co., Inc, North Wales, Pennsylvania, USA.

b Department of Oncology, Sidney Kimmel Comprehensive Cancer Center , Johns Hopkins University, Baltimore, Maryland, USA.

出版信息

J Biopharm Stat. 2017;27(6):990-1008. doi: 10.1080/10543406.2017.1295250. Epub 2017 Mar 27.

DOI:10.1080/10543406.2017.1295250
PMID:28346083
Abstract

The Vaccine Adverse Event Reporting System (VAERS) and other product surveillance systems compile reports of product-associated adverse events (AEs), and these reports may include a wide range of information including age, gender, and concomitant vaccines. Controlling for possible confounding variables such as these is an important task when utilizing surveillance systems to monitor post-market product safety. A common method for handling possible confounders is to compare observed product-AE combinations with adjusted baseline frequencies where the adjustments are made by stratifying on observable characteristics. Though approaches such as these have proven to be useful, in this article we propose a more flexible logistic regression approach which allows for covariates of all types rather than relying solely on stratification. Indeed, a main advantage of our approach is that the general regression framework provides flexibility to incorporate additional information such as demographic factors and concomitant vaccines. As part of our covariate-adjusted method, we outline a procedure for signal detection that accounts for multiple comparisons and controls the overall Type 1 error rate. To demonstrate the effectiveness of our approach, we illustrate our method with an example involving febrile convulsion, and we further evaluate its performance in a series of simulation studies.

摘要

疫苗不良事件报告系统(VAERS)和其他产品监测系统收集与产品相关的不良事件(AE)报告,这些报告可能包含广泛的信息,包括年龄、性别和同时接种的疫苗。在利用监测系统监测上市后产品安全性时,控制诸如此类可能的混杂变量是一项重要任务。处理可能的混杂因素的常用方法是将观察到的产品 - AE组合与调整后的基线频率进行比较,其中通过对可观察特征进行分层来进行调整。尽管诸如此类方法已被证明是有用的,但在本文中,我们提出一种更灵活的逻辑回归方法,该方法允许使用所有类型的协变量,而不是仅依赖分层。实际上,我们方法的一个主要优点是,通用回归框架提供了纳入诸如人口统计学因素和同时接种的疫苗等额外信息的灵活性。作为我们协变量调整方法的一部分,我们概述了一种信号检测程序,该程序考虑了多重比较并控制了总体I型错误率。为了证明我们方法的有效性,我们用一个涉及热性惊厥的例子来说明我们的方法,并在一系列模拟研究中进一步评估其性能。

相似文献

1
Logistic Regression Likelihood Ratio Test Analysis for Detecting Signals of Adverse Events in Post-market Safety Surveillance.用于上市后安全监测中不良事件信号检测的逻辑回归似然比检验分析
J Biopharm Stat. 2017;27(6):990-1008. doi: 10.1080/10543406.2017.1295250. Epub 2017 Mar 27.
2
Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.三价重组流感疫苗的上市后安全性监测:向疫苗不良事件报告系统提交的报告
Vaccine. 2017 Oct 9;35(42):5618-5621. doi: 10.1016/j.vaccine.2017.08.047. Epub 2017 Sep 5.
3
Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.2009 年 10 月 1 日至 2010 年 1 月 31 日期间,向美国疫苗不良事件报告系统报告的甲型 H1N1 流感单价疫苗不良事件。
Vaccine. 2010 Oct 21;28(45):7248-55. doi: 10.1016/j.vaccine.2010.09.021. Epub 2010 Sep 16.
4
Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.美国2005年7月至2013年6月,成人三价减毒活流感疫苗上市后监测,疫苗不良事件报告系统(VAERS)
Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22.
5
Implementing near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD).利用临床实践研究数据链(CPRD)实施近乎实时的疫苗安全监测。
Vaccine. 2017 Dec 14;35(49 Pt B):6885-6892. doi: 10.1016/j.vaccine.2017.09.022. Epub 2017 Oct 19.
6
Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.意大利接种 MF59 佐剂 H1N1v 疫苗后的不良事件报告上市后监测。
Vaccine. 2011 May 9;29(20):3708-13. doi: 10.1016/j.vaccine.2011.02.097. Epub 2011 Mar 12.
7
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.免疫接种后安全性监测:疫苗不良事件报告系统(VAERS)——美国,1991 - 2001年
MMWR Surveill Summ. 2003 Jan 24;52(1):1-24.
8
Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.2岁以下儿童接种灭活流感疫苗后的不良事件:1990 - 2003年疫苗不良事件报告系统报告分析
Pediatrics. 2005 Feb;115(2):453-60. doi: 10.1542/peds.2004-1519.
9
Continuous sequential boundaries for vaccine safety surveillance.疫苗安全性监测的连续序贯界限
Stat Med. 2014 Aug 30;33(19):3387-97. doi: 10.1002/sim.6161. Epub 2014 Apr 1.
10
Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.在6至23个月大的儿童中,接种三价灭活流感疫苗(TIV)后很少报告有严重不良事件。
Vaccine. 2009 Jul 9;27(32):4278-83. doi: 10.1016/j.vaccine.2009.05.023. Epub 2009 May 28.

引用本文的文献

1
A Statistical Framework to Detect and Quantify Operator-Learning Curves in Medical Device Safety Evaluation.一种用于在医疗设备安全评估中检测和量化操作员学习曲线的统计框架。
Med Devices (Auckl). 2025 Jul 2;18:361-375. doi: 10.2147/MDER.S520191. eCollection 2025.
2
A semiparametric quantile regression rank score test for zero-inflated data.用于零膨胀数据的半参数分位数回归秩得分检验。
Biometrics. 2025 Apr 2;81(2). doi: 10.1093/biomtc/ujaf050.
3
Foundational model aided automatic high-throughput drug screening using self-controlled cohort study.
利用自我对照队列研究的基础模型辅助自动高通量药物筛选
medRxiv. 2024 Sep 16:2024.08.04.24311480. doi: 10.1101/2024.08.04.24311480.
4
Ensuring safety and efficacy in combination products: regulatory challenges and best practices.确保组合产品的安全性和有效性:监管挑战与最佳实践。
Front Med Technol. 2024 Jul 10;6:1377443. doi: 10.3389/fmedt.2024.1377443. eCollection 2024.
5
Safety signal detection with control of latent factors.安全性信号检测与潜伏因素控制。
Stat Med. 2024 Mar 30;43(7):1397-1418. doi: 10.1002/sim.10015. Epub 2024 Jan 31.
6
Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.用于探索药物-宿主因素相互作用的自发不良事件报告数据库的统计方法。
BMC Med Res Methodol. 2023 Mar 27;23(1):71. doi: 10.1186/s12874-023-01885-w.
7
Predicting the Severity of Adverse Events on Osteoporosis Drugs Using Attribute Weighted Logistic Regression.使用属性加权逻辑回归预测骨质疏松症药物不良事件的严重程度。
Int J Environ Res Public Health. 2023 Feb 13;20(4):3289. doi: 10.3390/ijerph20043289.
8
Likelihood-Ratio-Test Methods for Drug Safety Signal Detection from Multiple Clinical Datasets.基于多个临床数据集的药物安全性信号检测的似然比检验方法。
Comput Math Methods Med. 2019 Feb 19;2019:1526290. doi: 10.1155/2019/1526290. eCollection 2019.
9
Efficient methods for signal detection from correlated adverse events in clinical trials.从临床试验中相关不良事件进行信号检测的有效方法。
Biometrics. 2019 Sep;75(3):1000-1008. doi: 10.1111/biom.13031. Epub 2019 Mar 29.
10
Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.安全数据来源及设计与分析的统计策略:上市后监测
Ther Innov Regul Sci. 2018 Mar;52(2):159-169. doi: 10.1177/2168479017741112. Epub 2018 Jan 8.